Genesis Molecular AI

Genesis Molecular AI develops GEMS, a generative and predictive molecular AI platform that designs and optimizes small‑molecule drug candidates, including the Pearl diffusion model for structure prediction. The company advances an internal discovery pipeline and partners with pharma on AI‑enabled discovery; recent collaborations include Gilead (2024) and Incyte (2025). It is privately held, headquartered in Burlingame, California, with a fully integrated laboratory in San Diego.